PONTARA, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.495
AS - Asia 829
EU - Europa 605
AF - Africa 36
SA - Sud America 20
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 5.989
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.491
CN - Cina 351
SG - Singapore 306
IT - Italia 126
VN - Vietnam 123
FI - Finlandia 104
SE - Svezia 101
DE - Germania 71
FR - Francia 47
GB - Regno Unito 41
RU - Federazione Russa 37
CI - Costa d'Avorio 34
HK - Hong Kong 28
BR - Brasile 20
NL - Olanda 19
UA - Ucraina 17
BE - Belgio 11
ES - Italia 8
IE - Irlanda 7
IN - India 4
CA - Canada 3
EU - Europa 3
JP - Giappone 3
TR - Turchia 3
AT - Austria 2
DK - Danimarca 2
IQ - Iraq 2
MA - Marocco 2
RO - Romania 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BG - Bulgaria 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
EE - Estonia 1
HU - Ungheria 1
IR - Iran 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MO - Macao, regione amministrativa speciale della Cina 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 5.989
Salva come PNG Salva come JPEG
Città #
Fairfield 780
Chandler 440
Woodbridge 390
Ashburn 339
Houston 314
Cambridge 278
Seattle 272
Wilmington 243
Ann Arbor 230
Singapore 162
Jacksonville 118
Dong Ket 117
Santa Clara 104
Boardman 98
Beijing 92
Princeton 90
San Diego 72
Padova 55
Nanjing 48
Medford 47
Helsinki 43
Abidjan 34
Roxbury 33
Hong Kong 27
Des Moines 23
New York 15
Shenyang 15
Changsha 14
Washington 14
Norwalk 13
Hebei 11
Jiaxing 11
London 9
Milan 9
Hefei 8
Waanrode 8
Dublin 7
Nanchang 7
Redwood City 7
Borås 5
Dallas 5
Florence 5
Kunming 5
Guangzhou 4
Ho Chi Minh City 4
Indiana 4
Los Angeles 4
Madrid 4
Tianjin 4
Zhengzhou 4
Bologna 3
Brussels 3
Chicago 3
Dearborn 3
Istanbul 3
Kilburn 3
Pune 3
Southwark 3
Tappahannock 3
Vicenza 3
Agrigento 2
Baoding 2
Bethel Park 2
Cascina 2
Chengdu 2
Chiswick 2
Chongqing 2
Falls Church 2
Frankfurt am Main 2
Fuzhou 2
Hangzhou 2
Jinan 2
Kharkiv 2
Monte San Giusto 2
Olbia 2
Ospedaletto Euganeo 2
Parma 2
Phoenix 2
Ponte di Piave 2
Rockville 2
Savona 2
Shanghai 2
Simi Valley 2
Stockholm 2
Tomblaine 2
Wenzhou 2
Wuhan 2
Yellow Springs 2
Yuncheng 2
Agordo 1
Aliança 1
Anaheim 1
Anápolis 1
Araraquara 1
Asir 1
Atlanta 1
Auckland 1
Baghdad 1
Betim 1
Blumenau 1
Totale 4.744
Salva come PNG Salva come JPEG
Nome #
Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease. 162
Haemostatic patterns and bleeding scores of a genetically characterised Italian family with combined haemophilia A and type 1 von Willebrand disease 134
A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function. 132
Usefulness of the Total Thrombus-Formation Analysis System (T-TAS) in the diagnosis and characterization of von Willebrand disease 132
Type IIB von Willebrand Factor induces phospholipase A2 activation and cytosolic Ca2+ increase in platelets 131
Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. 128
The p.R1819_C1948delinsS mutation makes von Willebrand factor ADAMTS13-resistant and reduces its collagen-binding capacity 127
New insight into the Hypercoagulability of Cushing's Syndrome 125
Spontaneous hemarthrosis in combined Glanzmann thrombasthenia and type 2N von Willebrand disease. 124
Loss of cysteine 584 impairs the storage and release, but not the synthesis of von Willebrand factor 123
Severe, recessive type 1 is a discrete form of von Willebrand disease: The lesson learned from the c.1534-3C>A von Willebrand factor mutation 122
Abnormally large von Willebrand factor multimers in Henoch-Schönlein purpura. 120
von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. 116
Higher and lower active circulating VWF levels: different facets of von Willebrand disease 111
von Willebrand factor abnormalities in aortic valve stenosis:pathophysiology and impact on bleeding. 110
Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns 108
Acquired factor VIII:C inhibitor in a patient with Sjögren's syndrome: successful treatment with steroid and immunosuppressive therapy. 107
A novel von Willebrand factor mutation (11372S) associated with type 2B-like von Willebrand disease: An elusive phenotype and a difficult diagnosis 104
Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. 103
Hypercortisolism and pregnancy upregulate von Willebrand factor through different mechanisms: report on a pregnant patient with Cushing's syndrome. 103
C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor 97
Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. 97
Diagnosis and follow-up of thrombotic thrombocytopenic purpura by means of von Willebrand factor collagen binding assay. 97
Abnormal collagen binding activity of 2A von Willebrand factor: evidence that the defect depends only on the lack of large multimers. 96
Inhibitory effect of prostacyclin and nitroprusside on type IIB von Willebrand factor-promoted platelet activation. 95
Multiple von Willebrand factor mutations in patients with recessive type 1 von Willebrand disease. 95
EDTA dependent pseudothrombocytopenia caused by antibodies against the cytoadhesive receptor of platelet gpIIB-IIIA. 94
Platelet aggregation induced by plasma from type IIB von Willebrand's disease patients is associated with an increase in cytosolic Ca2+ concentration. 92
Combined partial exon skipping and cryptic splice site activation as a new molecular mechanism for recessive type 1 von Willebrand disease. 91
A common ancestor more than 10,000 years old for patients with R854Q-related type 2N von Willebrand's disease in Italy. 88
Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor. 87
Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity? 87
Microsatellite (GT)(n) repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions. 85
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis. 85
First report of combined factor VII Padua defect and von Willebrand's disease due to casual association of the two defects. 84
Type I Padua: a new variant of von Willebrand's disease. 84
Combined exon skipping and cryptic splice activation as a new molecular mechanism for recessive type 1 von Willebrand disease. 83
Which assay is the most suitable to investigate von Willebrand factor functional activity? 83
An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. 81
Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. 81
Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization. 80
A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers. 79
The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications. 78
Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. 78
Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors. 78
Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet von Willebrand factor content. 77
Demonstration that venous occlusion fails to release von Willebrand factor multimers. 77
On the release of von Willebrand factor from endothelial cells after venous occlusion. 75
Two novel mutations (Pro864His, Val867Glu) causing type 2A von Willebrand disease and affecting a single restriction site in exon 28. 73
Lack of multimer organization of von Willebrand factor in an acquired von Willebrand syndrome. 73
A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor 71
Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in systemic sclerosis: Frequency, clinical and prognostic correlates 71
Plasma and platelet von Willebrand factor abnormalities in patients with uremia: lack of correlation with uremic bleeding. 68
Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies 66
Fainting induces an acute increase in the concentration of plasma factor VIII and von Willebrand factor. 64
On the discrepant post-DDAVP increase of FVIII:C and von Willebrand factor in some patients with severe von Willebrand's disease. 61
An apparent silent nucleotide substitution (c.7056C>T) in the von Willebrand factor gene is responsible for type 1 von Willebrand disease. 60
Type 2N von Willebrand disease due to Arg91Gln substitution and a cytosine deletion in exon 18 of the von Willebrand factor gene. 59
Preliminary hemocompatibility assessment of an innovative material for blood contacting surfaces 58
DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor. 57
Discrepant increase in factor VIII: C and von Willebrand factor after DDAVP infusion in a patient with variant von Willebrand's disease. 56
A Machine-Learning Model for the Prognostic Role of C-Reactive Protein in Myocarditis 53
Identifying carriers of type 2N von Willebrand disease: procedures and significance. 53
Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion. 49
Combined hemophilia A and type 2 von Willebrand's disease: defect of both factor VIII level and factor VIII binding capacity of von Willebrand factor. 46
Serum Anti-Heart and Anti-Intercalated Disk Autoantibodies: Novel Autoimmune Markers in Cardiac Sarcoidosis 43
DDAVP infusion: a possible useful tool in the diagnosis of the haemophilia A carrier state. 37
Fulminant Myocarditis: When One Size Does Not Fit All – A Critical Review of the Literature 28
Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity? 25
The Role of the Immune System in Pathobiology and Therapy of Myocarditis: A Review 19
Cellular Immunology of Myocarditis: Lights and Shades—A Literature Review 13
Prevalence and Correlates of Anti-DSG2 Antibodies in Arrhythmogenic Right Ventricular Cardiomyopathy and Myocarditis: Immunological Insights from a Multicenter Study 6
Totale 6.035
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.139
article - articoli 24.139
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.278
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020216 0 0 0 0 0 0 0 0 0 93 75 48
2020/2021728 35 32 19 65 27 60 42 56 98 78 64 152
2021/2022984 49 105 152 64 12 70 72 104 23 31 145 157
2022/2023832 150 105 11 114 118 115 2 54 95 7 54 7
2023/2024426 23 50 62 42 46 55 39 17 7 11 35 39
2024/2025893 5 114 75 80 226 61 94 113 123 2 0 0
Totale 6.035